Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses turns positive
Q2 FY2026 other income / expenses was $710K, compared with -$129K a year earlier. Trailing-twelve-month other income / expenses was $3.53M.
Context
- Other income / expenses amounted to 15.4% of revenue in FY2025, down 10.6 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near $710K or moves back toward the trailing-twelve-month quarterly average of $881.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.5M USD
- Year-over-year change
- -30.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.5M | -30.4% |
| FY2024 | 2024-12-31 | 2.16M | +105.5% |
| FY2023 | 2023-12-31 | (39.13M) | +2.2% |
| FY2022 | 2022-12-31 | (39.99M) | -3083.7% |
| FY2021 | 2021-12-31 | (1.26M) | — |
Other Income / Expenses vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's LTM Jun 2026 other income / expenses of $3.53M is the 8th highest of the 9 companies compared; the peer median is $11.51M.
- Its year-over-year change of +174.6% is the 3rd highest of 9, against a peer median of +3.0%.
- Other income / expenses amounts to 64.3% of revenue for TSHA, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $158.99M | +525.4% | +142.9% | 1093.5% | |
| LTM Mar 2026 | $65.43M | +239.3% | — | 3.0% | |
| LTM Mar 2026 | $18.65M | -30.6% | +97.1% | 21.1% | |
| LTM Mar 2026 | $12.12M | +36.6% | +113.1% | — | |
| LTM Mar 2026 | $10.91M | -38.7% | +40.3% | 29.9% | |
| LTM Mar 2026 | $6.49M | -46.8% | +29.6% | — | |
| LTM Mar 2026 | $5.05M | +38.6% | — | — | |
| LTM Jun 2026 | $3.53M | +174.6% | — | 64.3% | |
| LTM Mar 2026 | -$33.33M | -9907.5% | — | 37.9% | |
| Peer median (excluding TSHA) | $11.51M | +3.0% | +97.1% | 29.9% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.5M | 15.45M | 8.33M | 9.77M |
| Cost of Revenue | 0 | 2.49M | 0 | 0 | 0 |
| Gross Profit | 0 | 15K | 15.45M | 8.33M | 9.77M |
| Gross Margin | — | 0.6% | 100.0% | 100.0% | 100.0% |
| Research & Development | 131.94M | 91.17M | 56.78M | 66M | 86.4M |
| Selling, General & Admin | 41.32M | 34.87M | 30.05M | 28.95M | 33.87M |
| Operating Expenses | 173.27M | 126.04M | 87.89M | 99.79M | 120.27M |
| Depreciation & Amortization | 492K | 2.49M | 1.37M | 1.25M | 1.15M |
| EBITDA | (172.6M) | (159.73M) | (105.2M) | (87.95M) | (107.79M) |
| EBITDA Margin | — | -6384.1% | -680.8% | -1055.5% | -1102.9% |
| Operating Income | (173.27M) | (126.03M) | (72.44M) | (91.46M) | (110.5M) |
| Operating Margin | — | -5037.1% | -468.8% | -1097.6% | -1130.6% |
| Interest Income | 172K | 249K | 3.57M | 6.94M | 9.22M |
| Interest Expense | 1.43M | 3.8M | 5M | 102K | 63K |
| Other Income / Expenses | (1.26M) | (39.99M) | (39.13M) | 2.16M | 1.5M |
| Income Before Tax | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Pre-Tax Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Net Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| EPS (Basic) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| EPS (Diluted) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| Weighted Avg Shares | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
| Weighted Avg Shares (Diluted) | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.